0000000001236562

AUTHOR

F. Piscaglia

showing 6 related works from this author

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score ma…

2022

Background: A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy. Materials and methods: We carried out a retrospective analysis of prospectively collected data from consecutive patients with non-viral advanced HCC, treated with atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers in 4 countries (Italy, Japan, Republic of Korea, and UK). The primary endpoint was overall survival (OS) with atezolizumab plus bevacizumab versus lenvatinib. Secondary endpoints were progression-free survival (PFS) with atezolizumab plus bevacizumab versus lenvatinib, and OS and PFS with atezolizumab plus bevacizumab versus soraf…

atezolizumabCancer ResearchSettore MED/12 - GastroenterologiaOncologysorafenib.NAFLDNASHadvanced HCCadvanced HCC NASH NAFLD lenvatinib sorafenib atezolizumab bevacizumablenvatinibbevacizumab
researchProduct

Cost-effectiveness of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma

2009

Oncologymedicine.medical_specialtyCost effectivenessComputed tomographyInternal medicineBiopsymedicinebiopsynon-invasive diagnosiAASLDHepatologymedicine.diagnostic_testRecallbusiness.industryNon invasiveGastroenterologycomputed tomographymedicine.diseaseAmerican Association for the Study of the Liver Diseasegadolinium-magnetic resonance imagingsmall hepatocellular carcinomaCost-effectiveneHepatocellular carcinomaRadiologybusinesscontrast-enhanced ultrasoundContrast-enhanced ultrasoundDigestive and Liver Disease
researchProduct

Metabolic disorders across hepatocellular carcinoma in Italy

2018

Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, pati…

OncologyMaleobesityDatabases FactualHepatocellular carcinoma0302 clinical medicineRisk FactorsProspective cohort studydiabetesMetabolic disorderLiver NeoplasmsDiabeteshepatocellular carcinomaMiddle AgedMetabolic syndromePortal vein thrombosisItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIADiabetes; Hepatocellular carcinoma; Metabolic syndrome; Obesitymetabolic syndrome03 medical and health sciencesDatabasesMetabolic DiseasesInternal medicinemedicineDiabetes MellitusHumansObesityFactualAgedNeoplasm StagingRetrospective StudiesHepatologybusiness.industryCarcinomaHepatocellularHepatologymedicine.diseaseSurvival AnalysisBCLC Stagediabetes; hepatocellular carcinoma; metabolic syndrome; obesity; Aged; Carcinoma Hepatocellular; Databases Factual; Diabetes Mellitus; Female; Humans; Italy; Liver Neoplasms; Male; Metabolic Diseases; Middle Aged; Multivariate Analysis; Neoplasm Staging; Obesity; Retrospective Studies; Risk Factors; Survival AnalysisdiabeteMultivariate AnalysisLiver functionMetabolic syndromebusiness
researchProduct

The changing scenario of hepatocellular carcinoma in Italy: an update

2021

Background and aims: Epidemiology of hepatocellular carcinoma (HCC) is changing in most areas of the world. This study aimed at updating the changing scenario of aetiology, clinical presentation, management and prognosis of HCC in Italy during the last 15 years. Methods: Retrospective analysis of the Italian Liver Cancer (ITA.LI.CA) database included 6034 HCC patients managed in 23 centres from 2004 to 2018. Patients were divided into three groups according to the date of cancer diagnosis (2004-2008, 2009-2013 and 2014-2018). Results: The main results were: (i) a progressive patient ageing; (ii) a progressive increase of non-viral cases and, particularly, of ‘metabolic’ and ‘metabolic + alc…

medicine.medical_specialtyPediatricsCarcinoma HepatocellularRadiofrequency ablationmedicine.medical_treatmentSettore MED/12 - GASTROENTEROLOGIAsurvivalepidemiology; hepatocellular carcinoma; survival; treatment; Humans; Italy; Neoplasm Staging; Retrospective Studies; Carcinoma Hepatocellular; Liver Neoplasmslaw.invention03 medical and health sciences0302 clinical medicinelawRetrospective StudieEpidemiologyMedicineHumansNeoplasm StagingRetrospective StudiesHepatologytreatmentbusiness.industryLiver NeoplasmsCarcinomaSettore MED/09 - MEDICINA INTERNACancerHepatocellularhepatocellular carcinomamedicine.diseaseCalendar periodItaly030220 oncology & carcinogenesisHepatocellular carcinomaEtiologyepidemiology; hepatocellular carcinoma; survival; treatment030211 gastroenterology & hepatologyepidemiologyPercutaneous ethanol injectionbusinessLiver cancer
researchProduct

Pattern of macrovascular invasion in hepatocellular carcinoma

2021

Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed …

Ablation TechniquesMaleRegistrieCirrhosisClinical BiochemistryMesenteric Veinloco-regional treatment030204 cardiovascular system & hematologyBiochemistryGastroenterologysurgeryAntineoplastic AgentLiver disease0302 clinical medicineNon-alcoholic Fatty Liver Diseasecirrhosis; hepatocellular carcinoma; loco-regional treatment; portal vein thrombosis; surgery; transplantationAscitesAblation Techniqueportal vein thrombosisRegistries030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaPortal VeinLiver DiseasesLiver NeoplasmsAsciteshepatocellular carcinomaGeneral MedicineMiddle AgedSorafenibPrognosisHepatitis BAlcoholicHepatitis CTumor BurdenSurvival RateItalyLiver NeoplasmHepatocellular carcinomaAsciteFemalemedicine.symptomLiver cancerHumanmedicine.medical_specialtyCarcinoma HepatocellularPrognosiAntineoplastic AgentsEnd Stage Liver Disease03 medical and health sciencesMesenteric VeinsHepatitis B ChronicInternal medicinemedicineHumansHepatectomyNeoplasm Invasivenessportal vein thrombosiLiver Diseases AlcoholicAgedNeoplasm Invasivene...Performance statusbusiness.industrycirrhosisCarcinomaSettore MED/09 - MEDICINA INTERNAPatient AcuityHepatocellularHepatitis C Chronicmedicine.diseaseLiver TransplantationTransplantationLiver functionbusinesscirrhositransplantationEuropean Journal of Clinical Investigation
researchProduct

SIUMB guidelines and recommendations for the correct use of ultrasound in the management of patients with focal liver disease

2019

The present document describes the SIUMB (Italian Society of Ultrasound in Medicine and Biology) guidelines for the use of ultrasound in the management of focal liver disease. The aim of the paper is to provide a clinical practice guideline for Italian physicians who are approaching the ultrasound study of a focal liver lesion. In particular, these guidelines provide simple indications, recommendations and general practice advices for the correct use of contrast-enhanced ultrasound (CEUS) in this scenario. They represent the SIUMB position of the ultrasound role in the diagnostic flow charts of the principal focal liver lesions, and are in agreement with other, previously published national…

medicine.medical_specialtySettore MED/09 - Medicina InternaHepatocellular carcinomaContrast enhanced ultrasoundCholangiocellular carcinoma; Contrast enhanced ultrasound; Focal nodular hyperplasia; Hemangioma; Hepatocellular carcinoma; MetastasisContrast MediaMetastasiCholangiocellular carcinoma030218 nuclear medicine & medical imagingMetastasis03 medical and health sciencesLiver disease0302 clinical medicineFocal nodular hyperplasiaInternal MedicineHumansMedicineRadiology Nuclear Medicine and imagingMedical physicsUltrasonographyUltrasound studybusiness.industryLiver NeoplasmsUltrasoundFocal nodular hyperplasiaGeneral MedicineGuidelinemedicine.diseaseClinical PracticeLiverLiver lesionOriginal Article030211 gastroenterology & hepatologyCholangiocellular carcinoma; Contrast enhanced ultrasound; Focal nodular hyperplasia; Hemangioma; Hepatocellular carcinoma; Metastasis; Contrast Media; Humans; Liver; Liver Neoplasms; UltrasonographybusinessHemangiomaContrast-enhanced ultrasound
researchProduct